Frontiers in Pharmacology (Dec 2022)
Curcumae Rhizoma - combined with Sparganii Rhizoma in the treatment of liver cancer: Chemical analysis using UPLC-LTQ-Orbitrap MSn, network analysis, and experimental assessment
- Jing Wei,
- Jing Wei,
- Xiaoping Wang,
- Xiaoping Wang,
- Ying Dong,
- Ying Dong,
- Xiangjian Zhong,
- Xiangjian Zhong,
- Xueyang Ren,
- Xueyang Ren,
- Ruolan Song,
- Ruolan Song,
- Jiamu Ma,
- Jiamu Ma,
- Axiang Yu,
- Axiang Yu,
- Qiqi Fan,
- Qiqi Fan,
- Jianling Yao,
- Jianling Yao,
- Dongjie Shan,
- Dongjie Shan,
- Fang Lv,
- Fang Lv,
- Yuan Zheng,
- Yuan Zheng,
- Qingyue Deng,
- Qingyue Deng,
- Xianxian Li,
- Xianxian Li,
- Yingyu He,
- Yingyu He,
- Shusheng Fan,
- Chongjun Zhao,
- Chongjun Zhao,
- Xiuhuan Wang,
- Xiuhuan Wang,
- Xiuhuan Wang,
- Ruijuan Yuan,
- Gaimei She,
- Gaimei She
Affiliations
- Jing Wei
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Jing Wei
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xiaoping Wang
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Xiaoping Wang
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Ying Dong
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Ying Dong
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xiangjian Zhong
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Xiangjian Zhong
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xueyang Ren
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Xueyang Ren
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Ruolan Song
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Ruolan Song
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Jiamu Ma
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Jiamu Ma
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Axiang Yu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Axiang Yu
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Qiqi Fan
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Qiqi Fan
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Jianling Yao
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Jianling Yao
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Dongjie Shan
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Dongjie Shan
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Fang Lv
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Fang Lv
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Yuan Zheng
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Yuan Zheng
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Qingyue Deng
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Qingyue Deng
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xianxian Li
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Xianxian Li
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Yingyu He
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Yingyu He
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Shusheng Fan
- State Key Laboratory of Natural Medicines, New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, China
- Chongjun Zhao
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Chongjun Zhao
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xiuhuan Wang
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Xiuhuan Wang
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- Xiuhuan Wang
- Beijing Huilongguan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, China
- Ruijuan Yuan
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Gaimei She
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
- Gaimei She
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing, China
- DOI
- https://doi.org/10.3389/fphar.2022.1027687
- Journal volume & issue
-
Vol. 13
Abstract
Objective:Curcumae Rhizoma–Sparganii Rhizoma (CR-SR) is a traditional botanical drug pair that can promote blood circulation, remove blood stasis, and treat tumors in clinics. The aim of the present study was to investigate the therapeutic material basis and potential mechanisms of CR-SR, CR, and SR for the treatment of liver cancer.Method: The chemical profile analyses of CR-SR, CR, and SR were performed by molecular networking and UPLC-LTQ-Orbitrap MSn. The anti-liver cancer activities of CR-SR, CR, and SR were assessed by using a zebrafish xenograft model in vivo for the first time and detected by the HepG2 cell model in vitro. Combining the network analysis and molecular docking, real-time quantitative polymerase chain reaction (RT-qPCR) experiments were undertaken to further explore the mechanisms of CR-SR, CR, and SR for the treatment of liver cancer.Results: In total, 65 components were identified in CR-SR, CR, and SR. Based on the clusters of molecular networking, a total of 12 novel diarylheptanoids were identified from CR-SR and CR. By combining our results with information from the literature, 32 sesquiterpenoids and 21 cyclic dipeptides were identified from CR-SR, CR, and SR. The anti-liver cancer activities were observed in both the drug pair and the single botanical drugs in vitro and in vivo, and the order of activity was CR-SR > CR > SR. They could downregulate the expression of proto-oncogene tyrosine-protein kinase Src (SRC), epidermal growth factor receptor (EGFR), estrogen receptor-α (ESR1), prostaglandin endoperoxide synthase 2 (PTGS2), and amyloid precursor protein (APP).Conclusion: Taken together, the present study provided an experimental basis for the therapeutic material basis and potential molecular mechanisms of CR-SR, CR, and SR. This study provided a novel insight for objective clinical treatment of liver cancer.
Keywords
- Curcumae Rhizoma - Sparganii Rhizoma
- liver cancer
- molecular networking
- UPLC-LTQ-Orbitrap MSn
- zebrafish xenograft model